Buttonwood Financial Advisors Inc. lessened its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 47.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,669 shares of the company's stock after selling 20,461 shares during the period. Buttonwood Financial Advisors Inc.'s holdings in Kenvue were worth $544,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently made changes to their positions in the business. SRS Capital Advisors Inc. raised its holdings in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares in the last quarter. Clarity Asset Management Inc. bought a new stake in Kenvue during the fourth quarter worth approximately $45,000. SBI Securities Co. Ltd. acquired a new position in Kenvue in the fourth quarter worth approximately $46,000. Continuum Advisory LLC grew its position in Kenvue by 2,071.1% in the first quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock worth $47,000 after buying an additional 1,864 shares during the last quarter. Finally, Golden State Wealth Management LLC grew its position in Kenvue by 292.0% in the first quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company's stock worth $74,000 after buying an additional 2,295 shares during the last quarter. Institutional investors own 97.64% of the company's stock.
Kenvue Stock Down 1.1%
Kenvue stock opened at $20.89 on Friday. The firm has a market cap of $40.07 billion, a price-to-earnings ratio of 37.97, a P/E/G ratio of 3.24 and a beta of 0.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.86 and a quick ratio of 0.60. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $25.17. The firm has a fifty day moving average price of $22.80 and a two-hundred day moving average price of $22.35.
Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The business's revenue was down 3.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.28 EPS. As a group, analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were issued a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.93%. Kenvue's payout ratio is 149.09%.
Analyst Ratings Changes
Several research analysts have issued reports on the stock. Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Evercore ISI assumed coverage on shares of Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target on the stock. UBS Group lifted their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Citigroup restated a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Finally, Redburn Atlantic assumed coverage on shares of Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target on the stock. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $25.33.
Get Our Latest Report on Kenvue
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
